Understanding the complexities of genetic conditions is crucial in providing timely and effective care for affected individuals. One such condition that has garnered attention within the medical community is Early Infantile Epileptic Encephalopathy Type 3 (EIEE3), which is associated with mutations in the SLC25A22 gene. DNA Labs UAE offers a comprehensive genetic test for this condition, aiming to provide essential information for affected families and their healthcare providers.
Understanding SLC25A22 and EIEE3
The SLC25A22 gene plays a vital role in the proper functioning of the human brain. Mutations in this gene can lead to Early Infantile Epileptic Encephalopathy Type 3, a severe form of epilepsy that manifests in the first few months of life. This condition is characterized by frequent seizures and significant developmental delays, posing a substantial challenge for affected individuals and their families.
Symptoms of EIEE3
The symptoms of EIEE3 can vary among affected individuals but generally include:
- Onset of seizures in the first few months of life, often resistant to standard epilepsy treatments.
- Developmental delays, including difficulties in reaching milestones such as sitting, crawling, or walking.
- Intellectual disability, which can range from mild to severe.
- Spasticity or muscle stiffness, which may affect movement and posture.
- Possible regression in skills or loss of abilities previously acquired.
It’s crucial for parents and caregivers to be aware of these symptoms, as early diagnosis and intervention can significantly impact the management of the condition.
SLC25A22 Gene Early Infantile Epileptic Encephalopathy Type 3 Genetic Test
DNA Labs UAE offers a specialized genetic test for diagnosing EIEE3, which involves analyzing the SLC25A22 gene for mutations known to cause the condition. This test is an invaluable tool for confirming the diagnosis, allowing for tailored treatment plans and management strategies to be developed. Furthermore, understanding the genetic basis of the condition can provide insights into potential risks for future pregnancies, offering families critical information for family planning.
The cost of the SLC25A22 Gene Early Infantile Epileptic Encephalopathy Type 3 Genetic Test is 3200 AED. While the cost may seem substantial, the value of the information it provides cannot be overstated. Early diagnosis and intervention can lead to better outcomes for affected individuals, making this test a crucial step in the care pathway.
For more information or to schedule a test, please visit DNA Labs UAE.
Conclusion
Early Infantile Epileptic Encephalopathy Type 3 is a challenging condition that affects not only the individual but also their families. Through advancements in genetic testing, such as the SLC25A22 genetic test offered by DNA Labs UAE, families can gain the knowledge needed to navigate this complex condition. With a cost of 3200 AED, this test provides invaluable insights that can lead to more effective management and care for those affected by EIEE3.
